Catawba Capital Management VA increased its position in Pfizer Inc. (NYSE:PFE) by 0.8% during the second quarter, Holdings Channel reports. The firm owned 199,376 shares of the biopharmaceutical company’s stock after buying an additional 1,501 shares during the period. Pfizer comprises about 1.7% of Catawba Capital Management VA’s investment portfolio, making the stock its 8th largest position. Catawba Capital Management VA’s holdings in Pfizer were worth $7,020,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. V Wealth Management LLC bought a new position in shares of Pfizer during the first quarter worth approximately $272,000. Rhenman & Partners Asset Management AB boosted its position in Pfizer by 8.4% in the first quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the biopharmaceutical company’s stock valued at $14,079,000 after buying an additional 37,000 shares during the period. Traynor Capital Management Inc. boosted its position in Pfizer by 0.9% in the first quarter. Traynor Capital Management Inc. now owns 27,790 shares of the biopharmaceutical company’s stock valued at $823,000 after buying an additional 254 shares during the period. Private Trust Co. NA boosted its position in Pfizer by 2.5% in the first quarter. Private Trust Co. NA now owns 114,956 shares of the biopharmaceutical company’s stock valued at $3,406,000 after buying an additional 2,776 shares during the period. Finally, Sigma Planning Corp boosted its position in Pfizer by 9.9% in the first quarter. Sigma Planning Corp now owns 88,504 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 7,972 shares during the period. 69.65% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 0.27% during mid-day trading on Friday, reaching $33.56. The company had a trading volume of 14,819,706 shares. The firm has a market capitalization of $203.56 billion, a PE ratio of 29.75 and a beta of 0.86. The stock’s 50-day moving average price is $34.29 and its 200 day moving average price is $34.19. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period last year, the business posted $0.56 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. Pfizer’s dividend payout ratio is presently 95.24%.
Several equities analysts have recently issued reports on the company. Argus reissued a “buy” rating and set a $39.00 target price on shares of Pfizer in a research note on Tuesday. Bank of America Corp. reissued a “buy” rating and set a $40.00 target price on shares of Pfizer in a research note on Tuesday, September 27th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Jefferies Group reduced their target price on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, September 13th. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.